Following a decision earlier this year to stop early a comparative Japanese Phase III trial with its oral ALK inhibitor Alecensa (alectinib) on highly positive results, Chugai Pharmaceutical Co. Ltd.will present new data from the study at the upcoming ASCO meeting.
ASCO Preview: Alecensa Bests Xalkori In Japan Head-To-Head
Chugai has unveiled new details of positive head-to-head Japanese clinical results for its breakthrough cancer therapy alectinib, which showed benefits over close rival crizotinib in lung cancer.